Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial

por Cassidy, J, Douillard, J-Y, Twelves, C, McKendrick, J J, Scheithauer, W, Bustová, I, Johnston, P G, Lesniewski-Kmak, K, Jelic, S, Fountzilas, G, Coxon, F, Díaz-Rubio, E, Maughan, T S, Malzyner, A, Bertetto, O, Beham, A, Figer, A, Dufour, P, Patel, K K, Cowell, W, Garrison, L P
Publicado 2006

CD13/Aminopeptidase N overexpression by basic fibroblast growth factor mediates enhanced invasiveness of 1F6 human melanoma cells

por Fontijn, D, Duyndam, M C A, van Berkel, M P A, Yuana, Y, Shapiro, L H, Pinedo, H M, Broxterman, H J, Boven, E
Publicado 2006

Clinical outcome and risk factors for recurrence in borderline ovarian tumours

por Yokoyama, Y, Moriya, T, Takano, T, Shoji, T, Takahashi, O, Nakahara, K, Yamada, H, Yaegashi, N, Okamura, K, Izutsu, T, Sugiyama, T, Tanaka, T, Kurachi, H, Sato, A, Tase, T, Mizunuma, H
Publicado 2006

Performance of cytology and human papillomavirus testing in relation to the menstrual cycle

por Sherman, M E, Carreon, J D, Schiffman, M
Publicado 2006

Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles

por Kramer, G, Schwarz, S, Hägg, M, Havelka, A Mandic, Linder, S
Publicado 2006

Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I–II s...

por Avallone, A, Delrio, P, Guida, C, Tatangelo, F, Petrillo, A, Marone, P, Cascini, L G, Morrica, B, Lastoria, S, Parisi, V, Budillon, A, Comella, P
Publicado 2006

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

por Weisberg, E, Manley, P, Mestan, J, Cowan-Jacob, S, Ray, A, Griffin, J D
Publicado 2006

Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature

por Des Guetz, G, Uzzan, B, Nicolas, P, Cucherat, M, Morere, J-F, Benamouzig, R, Breau, J-L, Perret, G-Y
Publicado 2006

The Wnt antagonist sFRP1 is downregulated in premalignant large bowel adenomas

por Caldwell, G M, Jones, C E, Taniere, P, Warrack, R, Soon, Y, Matthews, G M, Morton, D G
Publicado 2006

Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I–II study

por Tibaldi, C, Prochilo, T, Russo, F, Pennucci, M C, Del Freo, A, Innocenti, F, Fabbri, A, Falcone, A, Conte, P F, Baldini, E
Publicado 2006

Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer

por Kinoshita, A, Fukuda, M, Soda, H, Nagashima, S, Fukuda, M, Takatani, H, Kuba, M, Nakamura, Y, Tsurutani, J, Kohno, S, Oka, M
Publicado 2006

A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer

por Kang, H J, Chang, H M, Kim, T W, Ryu, M-H, Sohn, H-J, Yook, J H, Oh, S T, Kim, B S, Lee, J-S, Kang, Y-K
Publicado 2008

Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy

por Zlobec, I, Vuong, T, Compton, C C, Lugli, A, Michel, R P, Hayashi, S, Jass, J R
Publicado 2008

Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study

por Strasser, F, Lutz, T A, Maeder, M T, Thuerlimann, B, Bueche, D, Tschöp, M, Kaufmann, K, Holst, B, Brändle, M, von Moos, R, Demmer, R, Cerny, T
Publicado 2008

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients

por Del Mastro, L, Bruzzi, P, Nicolò, G, Cavazzini, G, Contu, A, D'Amico, M, Lavarello, A, Testore, F, Castagneto, B, Aitini, E, Perdelli, L, Bighin, C, Rosso, R, Venturini, Marco
Publicado 2005

The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines

por Kostrzewa-Nowak, D, Paine, M J I, Wolf, C R, Tarasiuk, J
Publicado 2005

Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar

por Fracasso, P M, Blum, K A, Ma, M K, Tan, B R, Wright, L P, Goodner, S A, Fears, C L, Hou, W, Arquette, M A, Picus, J, Denes, A, Mortimer, J E, Ratner, L, Ivy, S P, McLeod, H L
Publicado 2005

O(6)-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts

por Clemons, M, Kelly, J, Watson, A J, Howell, A, McElhinney, R S, McMurry, T B H, Margison, G P
Publicado 2005

A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index

por Colinet, B, Jacot, W, Bertrand, D, Lacombe, S, Bozonnat, M-C, Daurès, J-P, Pujol, J-L
Publicado 2005

A quantitative analysis of lymphatic vessels in human breast cancer, based on LYVE-1 immunoreactivity

por Kato, T, Prevo, R, Steers, G, Roberts, H, Leek, R D, Kimura, T, Kameoka, S, Nishikawa, T, Kobayashi, M, Jackson, D G, Harris, A L, Gatter, K C, Pezzella, F
Publicado 2005